UNSPSC 51422329: Betamethasone sodium phosphate

This classification denotes a therapeutic glucocorticoid with the molecular formula C22H28FO8P.2Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7BK02SCL3W, chemically known as 9-fluoro-11,17-dihydroxy-16-methyl-3,20-dioxopregna-1,4-dien-21-yl dihydrogen phosphate but more generally known as betamethasone sodium phosphate, which bears US NIH Compound Identifier 2367.

The base compound, Betamethasone, comes in many other forms, including base, acetate, acetate phosphate, acibutate, alcohol, benzoate, butyrate propionate, dihydrogen phosphate, dipropionate, phosphate, sodium, valerate, 17, 21-dipropionate, 17-acetate, 17 alpha-monopropionate, 17-benzoate, 17-dipropionate, 17-propionate, 17-propionate 21-methoxide, 17-valerate, 21-acetate, 21-disodium phosphate, 21-pentanoate, 21-phosphate, 21-phosphate disodium, and 21-valerate.

UNSPSC 51422329 Betamethasone sodium phosphate is a Commodity code that nominally identifies a single corticosteroid pharmaceutical product, yet the recent state and local opportunities posted under this code show little alignment with that specific drug. Seminole County, Florida's IFB60459723LAS solicits naloxone and safe drug deactivation systems for community health initiatives—a distinct pharmaceutical category—while the Texas Health and Human Services Commission's RFI HHS0017013 explores direct-to-manufacturer prescription program capabilities across a broad pharmacy benefit landscape, not betamethasone procurement specifically. The mismatch suggests that this code either carries legacy tagging or serves as a catch-all pharmaceutical category in some procurement systems, so prospective vendors should verify the actual scope of work in any posted opportunity rather than assume the code name reflects what is being bought.

The two opportunities signal activity in Florida and Texas, with the Seminole County work representing a concrete, near-term procurement (IFB with a July 26, 2023 response deadline, though that date has passed as of today) and the Texas HHS inquiry representing exploratory market outreach (RFI posted April 3, 2026 with immediate-response timing). The issuing bodies span county health departments and state health agencies, both with mission-critical procurement needs. Given the code's weak relationship to its nominal product scope and the sparse recent activity, vendors targeting pharmaceutical contracts should cross-reference opportunities against their actual product lines and capabilities rather than relying on UNSPSC classification alone for this particular code.